2-(2,6-dioxopiperidin-3-yl)-4-((2-methyl-1,3-dioxoisoindolin-5-yl)amino)isoindoline-1,3-dione

Catalog No.: 
ACQCSQ211
CAS No.: 
-
Molecular Formula: 
C22H16N4O6
Molecular Weight: 
432.39
2-(2,6-dioxopiperidin-3-yl)-4-((2-methyl-1,3-dioxoisoindolin-5-yl)amino)isoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$358.00InquiryInquiry
250mg95%$715.00InquiryInquiry
1g95%$1450.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2,6-dioxopiperidin-3-yl)-4-((2-methyl-1,3-dioxoisoindolin-5-yl)amino)isoindoline-1,3-dione
IUPAC Name2-(2,6-dioxopiperidin-3-yl)-4-((2-methyl-1,3-dioxoisoindolin-5-yl)amino)isoindoline-1,3-dione
Molecular FormulaC22H16N4O6
Molecular Weight432.39
SMILESCN1C(=O)C2=CC=C(NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2C1=O
InChI KeyFFGUMWDSDXLODK-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACQCSQ211 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJMDH279 route compound structure diagram
    ACJMDH2792307-00-8In Stock
  2. Plus
  3. ACYCKQ570 route compound structure diagram
    ACYCKQ5702093536-12-8In Stock
  4. Then
  5. ACQCSQ211 route product structure diagram
    ACQCSQ211-
Inquiry

2. ACQCSQ211 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMNXH235 route compound structure diagram
    ACMNXH23590224-73-0In Stock
  2. Plus
  3. ACMFGQ641 route compound structure diagram
    ACMFGQ64119171-19-8In Stock
  4. Then
  5. ACQCSQ211 route product structure diagram
    ACQCSQ211-
Inquiry

3. ACQCSQ211 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJMDH279 route compound structure diagram
    ACJMDH2792307-00-8In Stock
  2. Plus
  3. ACAZLH834 route compound structure diagram
    ACAZLH834959150-64-2In Stock
  4. Then
  5. ACQCSQ211 route product structure diagram
    ACQCSQ211-
Inquiry

Comments (0)